Skip to main content

Table 1 Clinicopathological characteristics of the melanoma cohort treated with anti-PD-1 therapy and the control melanoma cohort for CAF profiling

From: Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma

Characteristic Anti-PD-1 patients, No. (%) Objective response rate (CR/PR), No. (%) Disease control rate (CR/PR/SD), No. (%) Control patients, No. (%)
Overall 117 (100) 55 (47) 81 (69) 194 (100)
Age (y)
 < 65 67 (57) 34 (51) 51 (76) 87 (45)
 ≥ 65 50 (43) 21 (42) 30 (60) 107 (55)
Sex
 Male 70 (60) 35 (50) 48 (69) 110 (57)
 Female 47 (40) 20 (43) 33 (70) 84 (43)
Treatment
 Pembrolizumab 41 (35) 20 (49) 30 (73) 0
 Nivolumab 18 (15) 7 (39) 9 (50) 0
 Ipilimumab plus nivolumab 58 (50) 28 (48) 42 (72) 0
Prior immune checkpoint blockade
 Yes 36 (31) 13 (36) 22 (61) 0
 No 81 (69) 42 (52) 59 (73) 194 (100)
Mutation status
 BRAF 39 (33) 19 (49) 27 (69) NA
 NRAS 18 (15) 8 (44) 11 (61) NA
 KIT 2 (2) 1 (50) 2 (100) NA
 None detected 58 (50) 27 (47) 41 (71) NA
Stage at diagnosis
 I 24 (21) 14 (58) 19 (79) 77 (40)
 II 23 (20) 12 (52) 16 (70) 80 (41)
 III 38 (32) 16 (42) 24 (63) 30 (15)
 IV 20 (17) 6 (30) 13 (65) 3 (2)
 Not available 12 (10) 7 (58) 9 (75) 4 (2)
  1. Abbreviations: CAF cancer-associated fibroblast, CR complete response, NA not available, PR partial response, SD stable disease